AUTHORS
Rong He, MD, Peng Li, MD, PhD2, Ding Yi, MD, PhD3, Wei Xie, MD, PhD4, Xinjie Xu, PhD, FACMG5, Rong Mao6, Dong Chen, MD, PhD7, Ji Yuan, MD8, Jin Chen, MD9, Rashi Gupta, MD10, Nathanael Bailey, MD11, Horatiu Olteanu, M.D., Ph.D.12, Kaaren Reichard, MD13, Pedro Horna, M.D.14, Zhihui Li, MD15, Aref Al-Kali, M.D.16, Mithun Shah, MD, PhD17, Hassan B Alkhateeb, M.D.18, Mrinal M. Patnaik, MD, MBBS19, Abhishek Avinash Mangaonkar, MBBS20, Animesh Pardanani, PhD, MBBS21, Tariq Kewan, MD22, Naseema Gangat, MBBS23, Ayalew Tefferi, MD24, Kenneth Warrington, MD25, Matthew J Koster, MD26, David Viswanatha, MD27
AFFILIATIONS
1 Mayo Clinic, Rochester, United States
2 University of Utah, Salt Lake City, United States
3 Geisinger Health Care, Danville, United States
4 Oregon Health & Science University, Portland, United States
5 Mayo Clinic, Rochester, United States
6 University of Utah, Salt Lake City, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, United States
9 Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
10 University of Michigan Health-Sparrow, Lansing, United States
11 Mayo Clinic, Rochester, United States
12 Mayo Clinic, Rochester, United States
13 Mayo Clinic, Rochester, United States
14 Mayo Clinic, Rochester, United States
15 Beijing GoBroad Boren Hospital, Beijing, China
16 Mayo Clinic, Rochester, United States
17 Mayo Clinic, Rochester, United States
18 Mayo Clinic, Rochester, United States
19 Mayo Clinic, Rochester, United States
20 Mayo Clinic, Rochester, United States
21 Mayo Clinic, Rochester, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Mayo Clinic, Rochester, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States, Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States
ABSTRACT
Background: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is characterized by acquired UBA1 mutations with systemic inflammation and hematologic manifestations. As its presentation is highly heterogeneous and overlaps with rheumatologic, hematologic, and dermatologic disorders, identification of a pathogenic UBA1 mutation is essential for diagnosis. While most patients harbor UBA1 mutations with high variant allele frequency (VAF), the clinical significance of low-level mutations remains less well defined. VEXAS is also rare in women and has been primarily associated with monosomy X in limited reports. We retrospectively reviewed UBA1 mutations identified in a large next-generation sequencing (NGS) cohort and assessed their clinical significance in both male and female patients.
Methods: The molecular hematopathology laboratory database was queried for patients harboring pathogenic/likely pathogenic (P/LP) UBA1 mutations detected by a 47-gene myeloid neoplasm (MN)-focused NGS panel (analytical sensitivity 2%). Initial diagnostic VAF was analyzed. Clinical and laboratory data were obtained by electronic medical record review. Additional female cases were identified from three collaborating institutions. The study was IRB approved.
Results: Among 25,799 patients (13,930 males, 54%), 160 (0.6%) harbored P/LP UBA1 mutations (median 74 years, range 48–95). Among the 154 male patients, eight mutations were identified: M41T (n=70, 45%), M41L (39, 25%), M41V (28, 18%), c.118-1G>C (7, 5%), S56F (5, 3%), A478S (3, 2%), c.118-2del and c.118-5_119-1del (1, 1% each). VAF ranged from 2–95% (median 68%): 128 (83%) and 26 (17%) had VAF ≥30% and <30%, respectively. UBA1 was the sole mutation in 90/154 (58%) cases; common co-mutations included DNMT3A (25), TET2 (18), ASXL1 (8), EZH2 (6), SF3B1 and ZRSR2 (5 each).
Detailed clinical information was available for 73 male patients. Among 57 with VAF ≥30%, 56 had confirmed VEXAS and one had MDS with persistent inflammatory manifestations highly suggestive of VEXAS; 11 also had concurrent MNs (10 MDS, 1 CMML). Among 16 male patients with VAF <30%, the UBA1 mutation corroborated the clinical features and established the VEXAS diagnosis in all 7 patients with VAF ≥10% (none had a diagnostic MN). Of the nine remaining patients with VAF <10%, UBA1 provided key supporting evidence for VEXAS in three patients with autoinflammation despite low VAFs (2% M41V, 3% M41V, and 8% M41T), and one CMML patient exhibited VEXAS-like manifestations (5% A478S). The remaining five lacked convincing evidence of VEXAS, and UBA1 mutations represented subclonal events in a JAK2 V617F-positive MPN (transient, M41L, 2%), MDS-EB (c.118-2del, 3%), AML transformed from CMML (S56F, 2%), and two patients without a diagnostic MN (M41L, 2% and 3%).
6/160 (4%) UBA1-mutated patients were women. Three mutations were identified: c.118-2A>G (n=3), M41V (2), and c.480+1del (1). Two patients were diagnosed with VEXAS without associated MN: one with M41V (20%) and monosomy X, and one with c.118-2A>G (45%), normal karyotype, without UBA1 copy loss by microarray or skewed X-chromosome inactivation. The remaining four women all had JAK2 V617F-positive MPNs, including polycythemia vera (M41V, 18%) and primary myelofibrosis (c.480+1del, 2%), both without VEXAS; one essential thrombocythemia with documented rheumatologist visits (c.118-2A>G, 6%), and one unclassified MPN (c.118-2A>G, 45%), showing a significantly higher frequency of UBA1/JAK2 co-mutation than in men (P<0.0001). Review of NGS data from three additional institutions identified four more female UBA1-mutated patients (among 23,583 cases): one CML with VEXAS (M41V,19%), two CML without VEXAS (M41V, 24%; T603fs, 3%), and one patient without MN or VEXAS (c.118-2A>G, 21%). Overall, MPNs were identified in 7/10 (70%) female patients versus 1/73 (1%) males (P<0.0001).
Conclusions: UBA1 mutation testing is critical for establishing the diagnosis of VEXAS syndrome. While most patients have high mutation burden (VAF ≥30%), mutations with VAF 10–30% strongly support the diagnosis. In contrast, UBA1 mutations with VAF <10% require careful clinical correlation, as they may represent either bona fide VEXAS-associated clones or incidental subclonal mutations in MNs and CHIP/CCUS. Female patients showed enrichment of c.118-2A>G and M41V mutations and a strong association with MPNs, suggesting sex-specific biological differences that warrant further investigation.
DISCLOSURES
Rong He, MD: No relevant conflicts of interest to declare.